Vertex Pharmaceuticals holds the cleaner structural position, with growth as the main driver and profitability adding further support. Regeneron Pharmaceuticals still has the edge on valuation, which keeps the comparison from looking entirely one-sided. In the market, Regeneron Pharmaceuticals carries the stronger setup — intact trend against Vertex Pharmaceuticals's broken trend. That leaves a split case: the structural lead stays with Vertex Pharmaceuticals, but the market is not currently confirming it.
The comparison is based on similar long-term financial trajectories, not sector labels.
The clearest separation starts in growth, but profitability adds another real layer to the result. The overall score gap is 10 points in favour of Vertex Pharmaceuticals Incorporated.
Both operate in: Biotechnology
This comparison is based on industry proximity, not on functional trajectory similarity. REGN and VRTX share the same industry classification.
For a similarity-based comparison, see how Regeneron Pharmaceuticals and Vertex Pharmaceuticals each position within their functional peer groups in AssetNext.
Scores reflect position relative to comparable companies with similar long-term financial trajectories.
The largest gaps do not all point in the same direction.
Left means cheaper relative valuation. Higher means stronger structure.
Vertex Pharmaceuticals Incorporated occupies the cheaper side of the setup map, although Regeneron Pharmaceuticals, Inc. still holds the stronger structural profile.
Valuation position uses peer-relative PE percentile (idx_pct_pe) where available.
Earnings growth is one contributing factor within the growth lead.
Absolute pricing still looks more supportive for Regeneron Pharmaceuticals, with a forward P/E that is 5.8 turns lower there.
Growth is the clearest driver of the lead, with profitability adding further support — though valuation still provides a real counterweight.
Break down the REGN vs VRTX comparison across all dimensions with the full interactive tool.
Explore how REGN and VRTX each compare against other companies in their peer groups.
Rule-based, descriptive analysis only. Derived from peer percentile dimensions. Not investment advice. Peer groups are determined algorithmically based on structural similarity — not by sector classification alone.
AssetNext scores reflect each company's structural position within its functional peer group — not a ranking against all stocks simultaneously. Peers are identified by similarity across eight financial dimensions, including revenue growth trajectory, margin structure, capital intensity, and earnings stability. A score of 75 means the company ranks in the top quartile within its own peer group, not the entire market.
Four dimension scores drive the overall peer score: Growth (revenue trajectory and expansion dynamics), Quality (margin structure and capital efficiency), Valuation (peer-relative pricing on standard multiples), and Stability (earnings consistency and financial predictability). Each dimension is scored 0–100 relative to the peer group, then combined into an overall peer score using equal weighting.
Scores are recalculated periodically as underlying financial data is updated. All analysis is descriptive and rule-based — AssetNext describes structural realities and never issues buy, sell or hold recommendations.